Aulos Bioscience will present new Phase 2 data for AU-007, an AI-designed monoclonal antibody targeting IL-2, showing promising results in second-line melanoma treatment at the upcoming AACR Annual Meeting.
Aulos Bioscience has dosed the first patient in a Phase 2 trial evaluating AU-007, avelumab, and low-dose aldesleukin for non-small cell lung cancer (NSCLC).